Sustained Release Composition Eliminating Lag Phase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional drug release systems exhibit an initial and secondary release phase with a lag phase, necessitating additional oral administration to achieve therapeutic goals, which increases costs and inconvenience, especially for drugs requiring continuous delivery like peptides or proteins.
Innovation Solution
A sustained release composition comprising a polymer, bioactive agent, and release rate determined agent, where the release rate agent controls the bioactive agent's release, eliminating the lag phase by using TPGS in the oil phase to form microparticles that continuously release the agent without oral supplementation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug release systems are used, then the drug is released in initial and secondary phases with a lag phase, but additional oral administration is required to achieve therapeutic goals, increasing costs and inconvenience
Solution Approach 1:
The patent applies the continuity of useful action principle by designing a sustained release composition that maintains continuous drug release throughout the entire treatment period, eliminating the lag phase and secondary release phases present in traditional systems. The biodegradable polymer matrix continuously degrades and releases the bioactive agent, ensuring uninterrupted therapeutic action without requiring additional oral administrations.
Solution Approach 2:
The patent utilizes parameter changes by modifying the release rate characteristics of the drug delivery system. By adjusting the biodegradability parameters of the polymer matrix and the hydrophobicity parameters of the release rate determined agent, the system achieves continuous release kinetics rather than the phased release pattern of traditional systems, thereby eliminating the need for supplementary oral administration.
2Reliability
If traditional drug release systems are used, then the lag phase requires additional oral administration, but this increases costs and causes inconvenience
Solution Approach 1:
The sustained release composition provides continuous drug release from the initial moment of administration, eliminating the lag phase inherent in traditional systems. This continuous action ensures that therapeutic levels are maintained without requiring additional oral doses, thereby improving both efficacy reliability and administration convenience.
Solution Approach 2:
The biodegradable polymer matrix serves itself by automatically degrading and releasing the encapsulated bioactive agent throughout the treatment period. This self-service mechanism eliminates the need for external intervention or additional oral administrations to maintain therapeutic levels, thereby reducing costs and improving patient convenience.
3Duration of action of moving object
If biodegradable polymer drug carriers are used, then continuous and sustained release is achieved with single administration, but the traditional release curve still includes lag phase requiring oral administration
Solution Approach 1:
The patent changes the key parameters of the polymer matrix, specifically selecting biodegradable polymers with appropriate molecular weights and degradation rates, and incorporates release rate determined agents with specific hydrophobicity values. These parameter modifications ensure that the polymer degrades continuously from the start of administration, eliminating the lag phase and achieving immediate sustained release throughout the entire duration of action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides continuous drug release without a lag phase, eliminating the need for additional oral administration, thereby enhancing therapeutic efficacy and reducing side effects and costs.
Implementation Method 1
the release rate determined agent controls a release rate of the bioactive agent
Implementation Method 2
biodegradable polymers have been widely investigated as drug carriers
Implementation Method 3
mixing the oil phase with the aqueous phase to form the sustained release composition having a controlled release effect
Data Source
AI summary
A sustained release composition comprising a polymer and manufacturing method thereof. The sustained release composition comprises a polymer, a bioactive agent, and a release rate determined agent, wherein the release rate determined agent is dispersed in the sustained release composition to control the release rate of the bioactive agent. The method comprises providing an oil phase comprising a bioactive agent, a polymer, and a release rate determined agent; providing an aqueous phase comprising a surfactant; mixing the oil phase with the aqueous phase to form the sustained release composition having a controlled release effect.